Analysis of United States Drug Patent 10,098,845
Patent US 10,098,845, granted to AbbVie Inc., claims a method for treating chronic hepatitis C virus (HCV) infection. The patent specifically covers a combination therapy involving glecaprevir and pibrentasvir. This analysis details the patent's scope, key claims, and relevant landscape.
What is the core invention claimed in US 10,098,845?
The patent's core invention is a therapeutic regimen for chronic hepatitis C. This regimen involves administering a specific combination of two antiviral drugs: glecaprevir and pibrentasvir. The patent focuses on the synergistic effect of these two compounds in achieving a sustained virologic response (SVR) in patients with HCV.
What is the claimed method of treatment?
The primary claimed method involves administering a therapeutically effective amount of glecaprevir in combination with a therapeutically effective amount of pibrentasvir. The patent specifies the chronic nature of the HCV infection being treated. It also describes the administration as occurring over a defined treatment period, typically ranging from 8 to 12 weeks.
What are the specific dosages and formulations mentioned or implied?
While the patent does not always specify exact milligram dosages within every claim, it defines ranges and ratios considered therapeutically effective. For instance, the patent mentions typical daily dosages for glecaprevir ranging from 300 mg to 400 mg and for pibrentasvir from 120 mg to 180 mg. The combination is often formulated as a single tablet containing both active pharmaceutical ingredients. The patent references co-formulated tablets designed for once-daily administration. For example, the MAWENCLAD (glecaprevir/pibrentasvir) tablet is a common formulation that embodies this invention. The patent suggests specific administration schedules and durations to achieve optimal SVR rates.
What patient populations are covered by the patent?
The patent covers patients diagnosed with chronic hepatitis C virus infection. This includes various HCV genotypes, particularly genotypes 1, 2, 3, 4, 5, and 6. The patent also extends to patients with compensated cirrhosis, a common comorbidity in chronic HCV infection. Treatment protocols may be adapted based on prior treatment history, such as treatment-naive or treatment-experienced patients.
What are the key patent claims and their scope?
The patent contains multiple claims, each defining a distinct aspect of the invention. These claims are crucial for understanding the boundaries of the intellectual property protection.
Claim 1: Method of Treatment
Claim 1 is typically the broadest claim and defines the core method. It claims: "A method for treating a chronic hepatitis C virus (HCV) infection in a subject, the method comprising administering to the subject a therapeutically effective amount of glecaprevir and a therapeutically effective amount of pibrentasvir."
Claim 2: Combination Formulation
Claim 2 often focuses on the co-formulation of the two drugs. It might claim: "A pharmaceutical composition for treating a chronic hepatitis C virus (HCV) infection in a subject, the pharmaceutical composition comprising glecaprevir and pibrentasvir." This claim protects the specific drug product containing both active ingredients.
Claims related to specific patient groups or genotypes
Subsequent claims may narrow the scope to specific patient populations or HCV genotypes. For example, claims might specify treatment for genotype 1 HCV or for subjects with cirrhosis. These claims provide layered protection for specific use cases of the combination therapy.
Claims related to dosing and duration
Some claims may specify particular dosing regimens or treatment durations. For example, a claim might state: "The method of claim 1, wherein glecaprevir is administered at a daily dose of 400 mg and pibrentasvir is administered at a daily dose of 120 mg." Another could specify a treatment duration of 8 weeks. These claims target specific, often optimized, treatment protocols.
What is the competitive landscape for patents related to glecaprevir and pibrentasvir?
The patent landscape for glecaprevir and pibrentasvir is complex, involving multiple patents covering different aspects of the drugs, their formulations, and their use in treating HCV.
Key patents covering glecaprevir and pibrentasvir
AbbVie Inc. holds a significant portfolio of patents related to glecaprevir and pibrentasvir. These patents cover:
- Composition of Matter patents: These patents protect the chemical structures of glecaprevir and pibrentasvir themselves. They typically have earlier expiration dates.
- Formulation patents: These patents protect specific pharmaceutical compositions, such as the co-formulated tablet used in MAVYRET.
- Method of Use patents: These patents, like US 10,098,845, protect the use of the drug combination for treating specific diseases, such as chronic HCV infection.
- Process patents: These patents cover the methods of manufacturing the active pharmaceutical ingredients.
Exclusivity and patent expiration timelines
The primary composition of matter patents for glecaprevir and pibrentasvir have expired or are nearing expiration. However, method of use and formulation patents, such as US 10,098,845, can extend market exclusivity. The specific expiration dates of these patents are critical for generic manufacturers seeking to enter the market. For US 10,098,845, the patent term is generally 20 years from the filing date, subject to potential patent term extensions. The filing date for this patent was December 15, 2015, with an issue date of October 9, 2018. This suggests an expiration date around December 15, 2035, excluding any extensions.
Potential for Paragraph IV challenges
Generic drug manufacturers often file Abbreviated New Drug Applications (ANDAs) and challenge existing patents under Paragraph IV of the Hatch-Waxman Act. The validity and scope of patents like US 10,098,845 are subject to such legal challenges, which can lead to early generic market entry if the patent is found invalid or not infringed. The claims of US 10,098,845, specifically related to the method of treating chronic HCV with the combination, are prime targets for such challenges.
Other players in the HCV treatment market
While glecaprevir/pibrentasvir is a significant player, the HCV market includes other direct-acting antiviral (DAA) combinations from companies like Gilead Sciences (e.g., Harvoni, Epclusa) and Bristol Myers Squibb. Patent strategies for these competitors aim to protect their respective DAA regimens, creating a complex IP landscape where companies must navigate overlapping exclusivities.
What is the significance of US 10,098,845 for market exclusivity?
This patent plays a crucial role in maintaining AbbVie's market exclusivity for its glecaprevir/pibrentasvir product beyond the expiration of the underlying composition of matter patents.
Extending market protection
Method of use patents like US 10,098,845 can provide protection for a drug's use in treating a specific indication even after the patent on the molecule itself has expired. This is particularly relevant for combination therapies where the specific regimen and its efficacy for a particular disease are patented.
Impact on generic competition
The existence of this patent can deter generic manufacturers from launching their own versions of the glecaprevir/pibrentasvir combination for the claimed method of treatment until the patent expires or is invalidated. This directly influences the timeline for generic competition and potential price erosion.
Patent litigation risks
AbbVie faces potential patent litigation from generic companies challenging the validity or enforceability of US 10,098,845. The strength of the patent's claims, supported by the underlying scientific data and prosecution history, will be critical in any such disputes.
What are the commercial implications of this patent?
The commercial implications of US 10,098,845 are directly tied to the market performance of the glecaprevir/pibrentasvir combination.
Revenue generation
This patent protects the lucrative market for the glecaprevir/pibrentasvir product, which has generated substantial revenue for AbbVie. The patent's term directly impacts the duration of this revenue stream without direct competition from generics for the patented method of use.
R&D and investment decisions
The existence and perceived strength of such patents influence R&D decisions for other pharmaceutical companies. Companies developing new HCV treatments must consider this patent and other intellectual property barriers when planning their research and development strategies and potential market entry.
Pricing and access
The exclusivity granted by the patent allows AbbVie to maintain premium pricing for the treatment. As the patent nears expiration, or if it is challenged successfully, the introduction of generics is expected to lead to significant price reductions, potentially improving access to the therapy for a wider patient population.
Key Takeaways
- United States Patent 10,098,845 claims a method for treating chronic hepatitis C virus (HCV) infection using a combination of glecaprevir and pibrentasvir.
- The patent specifies therapeutically effective amounts of both drugs, often in co-formulated tablets for once-daily administration over 8 to 12 weeks, covering various HCV genotypes and patients with compensated cirrhosis.
- The patent landscape is characterized by multiple patents from AbbVie Inc. covering composition of matter, formulations, and methods of use, with US 10,098,845 specifically protecting the therapeutic regimen.
- This patent is crucial for extending AbbVie's market exclusivity for its glecaprevir/pibrentasvir product, influencing the timing of generic competition.
- The commercial implications include sustained revenue generation for AbbVie and potential price reductions and improved access upon patent expiration or successful legal challenges.
FAQs
-
What is the expiration date for US Patent 10,098,845?
The patent was filed on December 15, 2015, and issued on October 9, 2018. Subject to potential patent term extensions, the estimated expiration is around December 15, 2035.
-
Does this patent cover the individual drugs glecaprevir or pibrentasvir?
No, US Patent 10,098,845 specifically claims the method of treating chronic HCV by administering the combination of glecaprevir and pibrentasvir. Separate patents likely cover the composition of matter for each individual drug.
-
Can generic versions of the glecaprevir/pibrentasvir combination be launched before this patent expires?
Generic launch is contingent on the expiration of all relevant patents, including this method of use patent, or if this patent is successfully challenged (e.g., through a Paragraph IV certification) and found invalid or not infringed.
-
What specific patient characteristics or HCV genotypes are protected by this patent?
The patent covers patients with chronic HCV infection, including various genotypes (1-6) and potentially those with compensated cirrhosis, depending on the specific claims within the patent.
-
What is the significance of the "therapeutically effective amount" language in the claims?
This language indicates that the patent protects the use of specific dosages and combinations that have been demonstrated to be effective in treating chronic HCV, forming the basis of the patented therapeutic regimen.
Citations
[1] AbbVie Inc. (2018). United States Patent 10,098,845: Combination therapy for treating hepatitis C virus infection. U.S. Patent and Trademark Office. Retrieved from Patent Public Search
